Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 05 October 2015 | By Michael Mezher
The US Food and Drug Administration (FDA) is giving three duodenoscope makers 30 days to submit plans to conduct safety studies to help the agency understand the effectiveness of current cleaning instructions for these products.
In recent years, insufficient cleaning procedures have linked duodenoscopes to several bacterial outbreaks. The most notable was an outbreak of carbapenem-resistant Enterobacteriaceae (CRE) at the Ronald Reagan UCLA Medical Center in late 2014 and early 2015, which left two patients dead.
In February 2015, FDA released a safety communication warning healthcare professionals that design flaws could make these scopes difficult to clean, even if cleaning instructions are closely followed.
In May 2015, the agency's Gastroenterology-Urology Devices Panel met to discuss:
On 4 August 2015, after hearing the panel's recommendations, FDA released supplemental instructions intended to aid facilities that reprocess duodenoscopes to do so more effectively.
Shortly thereafter, on 12 August, FDA warned the three manufacturers marketing duodenoscopes in the US –Olympus, Fujifilm and Hoya – for failures related to cleaning procedures and reporting known infections.
Now, FDA is requiring the three aforementioned companies to develop postmarket surveillance studies at healthcare facilities that use their devices to assist the agency in collecting "useful data about the effectiveness of current reprocessing instructions and practices."
FDA says its investigations have shown that "reprocessing instructions are not always being followed correctly, as these instructions are labor intensive and prone to human error.”
The agency is asking the three manufacturers to answer the following questions related to their devices:
FDA says that the results of these studies should help the agency determine additional measures to reduce the risk of infection with these devices in the future.
Tags: Duodenoscope, CRE, Olympus, Fujifilm, Hoya, UCLA